Rybrevant (amivantamab)

pCPA File Number: 22311

Negotiation Status:

Concluded without agreement

Indication(s):

Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy

Sponsor/Manufacturer:

Janssen Inc.

CDA-AMC Project Number:

PC0289-000

pCPA Engagement Letter Issued:

2023-06-01

Negotiation Process Concluded:

2023-11-03